LT3222616T - N-[2-{4-[6-amino-5-(2,4-difluorbenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorfenil}etil]-l-alaninas ir jo tret-butilo esteris - Google Patents
N-[2-{4-[6-amino-5-(2,4-difluorbenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorfenil}etil]-l-alaninas ir jo tret-butilo esterisInfo
- Publication number
- LT3222616T LT3222616T LTEP17168533.2T LT17168533T LT3222616T LT 3222616 T LT3222616 T LT 3222616T LT 17168533 T LT17168533 T LT 17168533T LT 3222616 T LT3222616 T LT 3222616T
- Authority
- LT
- Lithuania
- Prior art keywords
- oxopyridin
- difluorobenzoyl
- difluorophenyl
- alanine
- ethyl
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1218640.9A GB201218640D0 (en) | 2012-10-17 | 2012-10-17 | Chemical compounds |
| GB201306881A GB201306881D0 (en) | 2013-04-16 | 2013-04-16 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3222616T true LT3222616T (lt) | 2019-09-10 |
Family
ID=49488610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP17168533.2T LT3222616T (lt) | 2012-10-17 | 2013-10-15 | N-[2-{4-[6-amino-5-(2,4-difluorbenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorfenil}etil]-l-alaninas ir jo tret-butilo esteris |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9388136B2 (https=) |
| EP (2) | EP3222616B1 (https=) |
| JP (2) | JP6260975B2 (https=) |
| KR (1) | KR102164536B1 (https=) |
| CN (2) | CN106496106B (https=) |
| AU (1) | AU2013333636B2 (https=) |
| BR (1) | BR112015008167B1 (https=) |
| CA (1) | CA2888928C (https=) |
| CY (2) | CY1119080T1 (https=) |
| DK (2) | DK3222616T3 (https=) |
| ES (2) | ES2743768T3 (https=) |
| HR (2) | HRP20171320T1 (https=) |
| HU (2) | HUE046132T2 (https=) |
| IL (2) | IL237863B (https=) |
| IN (1) | IN2015DN02721A (https=) |
| LT (1) | LT3222616T (https=) |
| MX (1) | MX364782B (https=) |
| NZ (1) | NZ706717A (https=) |
| PL (2) | PL3222616T3 (https=) |
| PT (2) | PT3222616T (https=) |
| RS (2) | RS59458B1 (https=) |
| RU (1) | RU2676329C2 (https=) |
| SG (2) | SG10201708166SA (https=) |
| SI (2) | SI3222616T1 (https=) |
| SM (2) | SMT201900524T1 (https=) |
| WO (1) | WO2014060742A1 (https=) |
| ZA (1) | ZA201501958B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046132T2 (hu) * | 2012-10-17 | 2020-02-28 | Macrophage Pharma Ltd | N-[2-{4-[6-amino-5-(2,4-difluor-benzoil)-2-oxopiridin-1(2H)-il]-3,5-difluor-fenil}etil]-l-alanin és annak tercbutil-észtere |
| GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| EP2258687B1 (en) | 2002-02-12 | 2012-12-26 | Glaxosmithkline LLC | Nicotinamide derivates useful as P38 inhibitors |
| MXPA04008822A (es) | 2002-03-14 | 2004-11-26 | Bayer Healthcare Ag | Aroilpiridinonas monociclicas. |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| BRPI0610368A8 (pt) | 2005-05-05 | 2015-09-08 | Glaxosmithkline Ip Dev Ltd | Modulação de enzima e de receptor |
| GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0608823D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
| GB0608837D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase |
| GB0608855D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase enzymes |
| ES2605727T3 (es) | 2006-05-04 | 2017-03-16 | Chroma Therapeutics Limited | Inhibidores de MAP cinasa p38 |
| GB0608821D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | DHFR enzyme inhibitors |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0621203D0 (en) | 2006-10-25 | 2006-12-06 | Chroma Therapeutics Ltd | PLK inhibitors |
| WO2008050096A1 (en) | 2006-10-25 | 2008-05-02 | Chroma Therapeutics Ltd. | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| US8962825B2 (en) | 2006-10-30 | 2015-02-24 | Glaxosmithkline Intellectual Property Development Limited | Hydroxamates as inhibitors of histone deacetylase |
| ATE524454T1 (de) | 2006-11-01 | 2011-09-15 | Chroma Therapeutics Ltd | Inhibitoren von ikk-beta serinthreoninproteinkinase |
| EA200900616A1 (ru) | 2006-11-01 | 2010-04-30 | Хрома Терапьютикс Лтд. | Ингибиторы ikk-бета серин-треонин протеинкиназы |
| EP2220044A1 (en) * | 2007-11-07 | 2010-08-25 | Chroma Therapeutics Limited | P38 map kinase inhibitors |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| US8778953B2 (en) | 2008-02-29 | 2014-07-15 | Chroma Therapeutics Ltd. | Inhibitors of P38 map kinase |
| CN102036979A (zh) | 2008-04-23 | 2011-04-27 | 色品疗法有限公司 | IKK-β丝氨酸苏氨酸蛋白激酶抑制剂 |
| GB0807451D0 (en) | 2008-04-24 | 2008-05-28 | Chroma Therapeutics Ltd | Inhibitors of PLK |
| JP2011518817A (ja) | 2008-04-26 | 2011-06-30 | クロマ セラピューティクス リミテッド | ＩＫＫ−βセリン−、スレオニン−プロテインキナーゼ阻害剤としての置換されたチオフェンカルボキシアミド類 |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| GB0907120D0 (en) | 2009-04-24 | 2009-06-03 | Chroma Therapeutics Ltd | Inhibitors of IKK-ß serine-threonine protein kinase |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| GB201021467D0 (en) | 2010-12-17 | 2011-02-02 | Chroma Therapeutics Ltd | Imaging agents |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| HUE046132T2 (hu) * | 2012-10-17 | 2020-02-28 | Macrophage Pharma Ltd | N-[2-{4-[6-amino-5-(2,4-difluor-benzoil)-2-oxopiridin-1(2H)-il]-3,5-difluor-fenil}etil]-l-alanin és annak tercbutil-észtere |
-
2013
- 2013-10-15 HU HUE17168533A patent/HUE046132T2/hu unknown
- 2013-10-15 CA CA2888928A patent/CA2888928C/en not_active Expired - Fee Related
- 2013-10-15 WO PCT/GB2013/052689 patent/WO2014060742A1/en not_active Ceased
- 2013-10-15 PT PT17168533T patent/PT3222616T/pt unknown
- 2013-10-15 SI SI201331557T patent/SI3222616T1/sl unknown
- 2013-10-15 SG SG10201708166SA patent/SG10201708166SA/en unknown
- 2013-10-15 HR HRP20171320TT patent/HRP20171320T1/hr unknown
- 2013-10-15 ES ES17168533T patent/ES2743768T3/es active Active
- 2013-10-15 PL PL17168533T patent/PL3222616T3/pl unknown
- 2013-10-15 HU HUE13783363A patent/HUE035525T2/en unknown
- 2013-10-15 RS RSP20191330 patent/RS59458B1/sr unknown
- 2013-10-15 SM SM20190524T patent/SMT201900524T1/it unknown
- 2013-10-15 RS RS20170646A patent/RS56184B1/sr unknown
- 2013-10-15 CN CN201610944341.3A patent/CN106496106B/zh not_active Expired - Fee Related
- 2013-10-15 JP JP2015537346A patent/JP6260975B2/ja not_active Expired - Fee Related
- 2013-10-15 PT PT137833638T patent/PT2909175T/pt unknown
- 2013-10-15 LT LTEP17168533.2T patent/LT3222616T/lt unknown
- 2013-10-15 SM SM20170399T patent/SMT201700399T1/it unknown
- 2013-10-15 US US14/436,404 patent/US9388136B2/en not_active Expired - Fee Related
- 2013-10-15 EP EP17168533.2A patent/EP3222616B1/en active Active
- 2013-10-15 AU AU2013333636A patent/AU2013333636B2/en not_active Ceased
- 2013-10-15 IN IN2721DEN2015 patent/IN2015DN02721A/en unknown
- 2013-10-15 EP EP13783363.8A patent/EP2909175B1/en active Active
- 2013-10-15 PL PL13783363T patent/PL2909175T3/pl unknown
- 2013-10-15 MX MX2015004368A patent/MX364782B/es active IP Right Grant
- 2013-10-15 KR KR1020157012809A patent/KR102164536B1/ko not_active Expired - Fee Related
- 2013-10-15 DK DK17168533.2T patent/DK3222616T3/da active
- 2013-10-15 CN CN201380054069.6A patent/CN104781235B/zh not_active Expired - Fee Related
- 2013-10-15 BR BR112015008167-3A patent/BR112015008167B1/pt not_active IP Right Cessation
- 2013-10-15 RU RU2015115213A patent/RU2676329C2/ru active
- 2013-10-15 DK DK13783363.8T patent/DK2909175T3/en active
- 2013-10-15 SI SI201330714T patent/SI2909175T1/sl unknown
- 2013-10-15 ES ES13783363.8T patent/ES2635240T3/es active Active
- 2013-10-15 NZ NZ706717A patent/NZ706717A/en not_active IP Right Cessation
- 2013-10-15 SG SG11201502515VA patent/SG11201502515VA/en unknown
-
2015
- 2015-03-20 ZA ZA2015/01958A patent/ZA201501958B/en unknown
- 2015-03-22 IL IL237863A patent/IL237863B/en active IP Right Grant
-
2016
- 2016-06-15 US US15/183,612 patent/US9896417B2/en not_active Expired - Fee Related
-
2017
- 2017-07-17 CY CY20171100756T patent/CY1119080T1/el unknown
- 2017-10-11 JP JP2017197466A patent/JP6464244B2/ja not_active Expired - Fee Related
- 2017-12-25 IL IL256560A patent/IL256560B/en active IP Right Grant
-
2018
- 2018-01-03 US US15/861,586 patent/US10370332B2/en not_active Expired - Fee Related
-
2019
- 2019-09-23 CY CY20191101002T patent/CY1122194T1/el unknown
- 2019-10-15 HR HRP20191874TT patent/HRP20191874T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238130B (en) | Modified recombinant viruses containing the pr13.5 promoter and their uses | |
| IL233863A0 (en) | Pyridine derivatives, preparations containing them and their uses | |
| ZA201305129B (en) | NAv 1.7 KNOCKOUT MICE AND USES THEREOF | |
| EP2539799A4 (en) | GESTURES FOR REDUCING AND ENLARGING MULTIPLE SCREENS | |
| IL253950B (en) | Cyclic-converted uracils and their use | |
| IL237068A (en) | 1,3-dioxanomorphides and 1,3-dioxanocodides | |
| EP2872619A4 (en) | MESENCHYMAL STEM CELLS FROM HUMAN EMBRYONAL STEM CELLS, METHODS THEREFOR AND USES THEREOF | |
| PT2822936T (pt) | Derivados da aminoquinolina e suas utilizações | |
| EP2847649A4 (en) | IMAGE CAPTURE CONTROL SENSITIVE TO A GESTURE AND / OR OPERATION ON AN IMAGE | |
| IL216830A0 (en) | Isoquinoline, quinoline and quinazoline derivatives, compositions comprising the same and uses thereof | |
| ZA201402795B (en) | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same | |
| Drake et al. | Predicting artistic brilliance | |
| IL235681A0 (en) | 5- amino [1, 4] thiazines as 1 bace inhibitors | |
| EP2817773A4 (en) | CAPTURE OF DATA FOR INTERACTION OF A USER WITH PROMOTIONAL MATERIALS | |
| PL3004077T3 (pl) | Nowe związki 3,4-dihydro-2H-izochinolin-1-onu i 2,3-dihydro-izoindol-1-onu | |
| PL3004076T3 (pl) | Nowe związki 3,4-dihydro-2h-izochinolin-1-onowe i 2,3-dihydroizoindol-1-onowe | |
| PL3222616T3 (pl) | N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat | |
| IL238536B (en) | History of 6-oxo-6,1-dihydro-pyridazine for the treatment of hepatocellular carcinoma (hcc) | |
| Ekstrand et al. | The Art of Teaching Writing | |
| Niven | Writers Reading: Penelope Niven, MA'62 | |
| Ekstrand et al. | Writing Poetry | |
| GB201206552D0 (en) | Capturing,recording and managing multi-media communications 1 | |
| GB201206555D0 (en) | Capturing, recording and managing multi-media communications 2 | |
| AU336296S (en) | 'Re-Emerge' chiffon detail bustier dress | |
| AU2012904432A0 (en) | Enhanced gold recovery from refractory ores |